Drug Type Peptide drug conjugates |
Synonyms nendratareotide uzatansine, BTP-227, BTP-277 + [3] |
Target |
Mechanism SSTR2 modulators(Somatostatin receptor 2 modulators), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC83H109ClN14O20S4 |
InChIKeyJVPMJFUBODFGNB-UFDFPQQFSA-N |
CAS Registry1853254-97-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 2 | US | 08 Dec 2016 | |
Advanced cancer | Phase 2 | GB | 08 Dec 2016 | |
Neuroendocrine Carcinoma | Phase 2 | US | 08 Dec 2016 | |
Neuroendocrine Carcinoma | Phase 2 | GB | 08 Dec 2016 | |
Small Cell Lung Cancer | Phase 2 | US | 08 Dec 2016 | |
Small Cell Lung Cancer | Phase 2 | GB | 08 Dec 2016 | |
undifferentiated large cell lung cancer | Phase 2 | US | 08 Dec 2016 | |
undifferentiated large cell lung cancer | Phase 2 | GB | 08 Dec 2016 |